CLEC16A

Across TCGA pan-cancer cohorts, CLEC16A Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CLEC16A data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher CLEC16A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLEC16A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, READ, and BLCA are the cancer types where CLEC16A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
READ	OS	Median	II,III,IV	0.111	0.919	<.001	21	view →
BLCA	OS	Median	III,IV	0.170	0.582	.006	18	view →
UCEC	DFS	Median	All	0.974	0.827	.016	10	view →
SARC	DFS	Median	All	0.179	0.612	.024	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CLEC16A–THYM (OS)

Open the THYM breakdown →